Skip to content
Peptigraph home

Orforglipron Phase 2 trial (NCT05051579)

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
272
actual
Start
29 Sep 2021 (actual)
Primary completion
25 Aug 2022 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05051579 study arms
ArmTypeInterventionsDescription
12 milligram (mg) LY3502970ExperimentalDrug: LY3502970Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
24 mg LY3502970ExperimentalDrug: LY3502970Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
36 mg-1 LY3502970ExperimentalDrug: LY3502970Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
36 mg-2 LY3502970ExperimentalDrug: LY3502970Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
45 mg-1 LY3502970ExperimentalDrug: LY3502970Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
45 mg-2 LY3502970ExperimentalDrug: LY3502970Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
PlaceboPlacebo comparatorDrug: PlaceboParticipants received placebo administered orally once daily until 36 weeks.
Endpoints

Primary endpoint

NCT05051579 primary outcomes
MeasureTime frame
Percent Change From Baseline in Body Weight in LY3502970 and PlaceboBaseline, Week 26
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05051579 secondary outcomes
MeasureTime frame
Percent Change From Baseline in Body Weight in LY3502970 and PlaceboBaseline, Week 36
Change From Baseline in Body Weight in LY3502970 and PlaceboBaseline, Week 26
Change From Baseline in Body Weight in LY3502970 and PlaceboBaseline, Week 36
Change From Baseline in Waist Circumference in LY3502970 and PlaceboBaseline, Week 26
Change From Baseline in Waist Circumference in LY3502970 and PlaceboBaseline, Week 36
Change From Baseline in BMI in LY3502970 and PlaceboBaseline, Week 26
Change From Baseline in BMI in LY3502970 and PlaceboBaseline, Week 36
Percentage of Participants With >=5% Body Weight LossWeek 26
Percentage of Participants With >=10% Body Weight LossWeek 26
Percentage of Participants With >=5% Body Weight LossWeek 36
Percentage of Participants With >=10% Body Weight LossWeek 36
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05051579.

Daily oral orforglipron in adults with obesity, 36-week trial

Participants were randomised to orforglipron at 12, 24, 36 or 45 mg or to placebo once daily for 36 weeks.[2]

At week 26 the mean body weight change ranged from -8.6% to -12.6% across orforglipron groups and was -2.0% with placebo.[2]

At week 36 the range was -9.4% to -14.7% against -2.3% with placebo.[2]

A weight reduction of at least 10% by week 36 occurred in 46 to 75% of orforglipron recipients and 9% of placebo recipients.[2]

Gastrointestinal events led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts.[2]

Sources

  1. 1A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026

Found an error? Report a correction.